GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medipost Co Ltd (XKRX:078160) » Definitions » Financial Strength

Medipost Co (XKRX:078160) Financial Strength : 6 (As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Medipost Co Financial Strength?

Medipost Co has the Financial Strength Rank of 6.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

Medipost Co did not have earnings to cover the interest expense. Medipost Co's debt to revenue ratio for the quarter that ended in Dec. 2023 was 0.17. As of today, Medipost Co's Altman Z-Score is 1.54.


Competitive Comparison of Medipost Co's Financial Strength

For the Biotechnology subindustry, Medipost Co's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medipost Co's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medipost Co's Financial Strength distribution charts can be found below:

* The bar in red indicates where Medipost Co's Financial Strength falls into.



Medipost Co Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Medipost Co's Interest Expense for the months ended in Dec. 2023 was ₩-152 Mil. Its Operating Income for the months ended in Dec. 2023 was ₩-9,696 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩7,985 Mil.

Medipost Co's Interest Coverage for the quarter that ended in Dec. 2023 is

Medipost Co did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Medipost Co's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2023 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(3658.228 + 7984.895) / 68171.152
=0.17

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Medipost Co has a Z-score of 1.54, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of 1.54 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medipost Co  (XKRX:078160) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Medipost Co has the Financial Strength Rank of 6.


Medipost Co Financial Strength Related Terms

Thank you for viewing the detailed overview of Medipost Co's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Medipost Co (XKRX:078160) Business Description

Traded in Other Exchanges
N/A
Address
21, Daewangpangyo-ro 644, Bundang-gu, Gyeonggi-do, Seongnam, KOR
Medipost Co Ltd is a Korea-based stem cell biotechnology company. The company is engaged in developing products to meet unmet medical needs. The company operates its business through four distinct segments: Stem Cell Therapeutics, Cord Blood Bank, Cosmetics, and Health Supplements. The Cord Blood Bank Division is involved in collecting and storing stem cells from the newborn's umbilical cord. The Stem Cell Therapeutics division manufactures allogeneic stem cell drug products. The Health Supplements division offers vitamins and nutritional supplements. The Cosmetics division is involved in the sales and marketing of natural cosmetics.

Medipost Co (XKRX:078160) Headlines

No Headlines